{"entity":{"id":"endopredict","kind":"drug","name":"EndoPredict","aka":[],"tldr":"A 12-gene test that combines gene activity with tumour size and lymph nodes to say whether hormone therapy alone is enough, and whether to continue it beyond five years.","summary":"EndoPredict (Sividon, acquired by Myriad Genetics in 2016) is CE-marked and validated in the ABCSG-6 and ABCSG-8 trial cohorts and in TransATAC, where EPclin identified a low-risk group with about 4% distant recurrence at 10 years on endocrine therapy alone and predicted late recurrence between years five and ten. NICE DG34 recommends it for guiding chemotherapy decisions in the NHS; it is offered in the US as a laboratory-developed test. Because it includes clinical variables, EPclin outperformed purely molecular scores in head-to-head comparisons on the TransATAC cohort.","status":"established","asOf":"2026-09-10","links":[{"label":"NICE DG34","url":"https://www.nice.org.uk/guidance/dg34"},{"label":"Myriad: EndoPredict","url":"https://myriad.com/oncology/endopredict/"}],"tags":["test"],"related":["oncotype-dx","prosigna"],"cancers":["breast-hr-positive"],"sections":[],"technologies":["rna-seq"],"targets":[],"drugs":[],"companies":["myriad-genetics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: EPclin low means chemotherapy can safely be omitted and the case for extended hormone therapy is weak; EPclin high means the opposite."],"brand":"EndoPredict","modality":"Gene-expression prognostic assay (12-gene EPclin score)","mechanism":"RT-PCR of eight cancer genes and three reference genes gives a molecular score, combined with tumour size and nodal status into the EPclin score predicting 10-year distant recurrence.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/endopredict/","neighbours":{"drug":[{"id":"breast-cancer-index","kind":"drug","name":"Breast Cancer Index","route":"/drugs/breast-cancer-index/"},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/"},{"id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"company":[{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/"}]}}